Harrow Health Inc (HROW) - Total Liabilities
Based on the latest financial reports, Harrow Health Inc (HROW) has total liabilities worth $391.19 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore HROW net asset momentum to track the company's year-over-year net asset growth rate.
Harrow Health Inc - Total Liabilities Trend (2005–2025)
This chart illustrates how Harrow Health Inc's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Harrow Health Inc to measure how efficiently the company converts operating cash flow to free cash.
Harrow Health Inc Competitors by Total Liabilities
The table below lists competitors of Harrow Health Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cpi Fim SA
WAR:OPG
|
Poland | zł4.75 Billion |
|
HIAG Immobilien Holding AG
SW:HIAG
|
Switzerland | CHF911.89 Million |
|
Zbit Semiconductor Inc. A
SHG:688416
|
China | CN¥133.03 Million |
|
Thai Union Group PCL
BK:TU
|
Thailand | ฿106.53 Billion |
|
J & J Snack Foods Corp
NASDAQ:JJSF
|
USA | $445.06 Million |
|
Shenzhen Hui Chuang Da Technology Co.Ltd
SHE:300909
|
China | CN¥1.42 Billion |
|
Hengtong Logistic Co Ltd
SHG:603223
|
China | CN¥1.19 Billion |
|
CITIC Guoan Information Industry Co Ltd
SHE:000839
|
China | CN¥4.90 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Harrow Health Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HROW market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 13.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.93 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Harrow Health Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Harrow Health Inc (2005–2025)
The table below shows the annual total liabilities of Harrow Health Inc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $347.39 Million | +8.67% |
| 2024-12-31 | $319.67 Million | +32.23% |
| 2023-12-31 | $241.75 Million | +85.77% |
| 2022-12-31 | $130.14 Million | +48.90% |
| 2021-12-31 | $87.40 Million | +185.19% |
| 2020-12-31 | $30.65 Million | -3.22% |
| 2019-12-31 | $31.67 Million | +28.21% |
| 2018-12-31 | $24.70 Million | +15.95% |
| 2017-12-31 | $21.30 Million | +2.34% |
| 2016-12-31 | $20.82 Million | +34.15% |
| 2015-12-31 | $15.52 Million | +641.66% |
| 2014-12-31 | $2.09 Million | +221.54% |
| 2013-12-31 | $650.63K | -8.31% |
| 2012-12-31 | $709.56K | -61.87% |
| 2011-12-31 | $1.86 Million | +33.83% |
| 2010-12-31 | $1.39 Million | +27.00% |
| 2009-12-31 | $1.09 Million | +43.31% |
| 2008-12-31 | $763.99K | +1.83% |
| 2007-12-31 | $750.24K | +19236.11% |
| 2006-12-31 | $3.88K | -21.62% |
| 2005-12-31 | $4.95K | -- |
About Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, in… Read more